This article is more than 5 years old. Information may no longer be current.

Regeneron reports $999 million in total revenue in second quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Regeneron reported $999 million in total revenue in the second quarter, a 50% increase compared with $666 million in the same quarter of 2014, according to a press release.

Net sales for Eylea (aflibercept) in the U.S. were reported at $655 million, a 58% increase compared with $415 million in the same quarter of 2014. Net sales for Eylea outside of the U.S. were reported at $338 million compared with $247 million in the same quarter of 2014.

Non-GAAP net income was reported at $328 million, or $3.29 per basic share and $2.89 per diluted share, in the second quarter compared with $289 million, or $2.88 per basic share and $2.47 per diluted share, in the same quarter of 2014.

GAAP net income was reported at $195 million, or $1.89 per basic share and $1.69 per diluted share, compared with $96 million, or $0.96 per basic share and $0.85 per diluted share, a year ago.